ANI Pharmaceuticals, Inc. announced that it has entered into a fee-for-service development agreement for a generic drug product with Sterling Pharmaceutical Services. The product will be developed by Sterling and transferred into ANI's facilities for commercial manufacture and marketing. The current annual market for this product is $60 million.